Merck & Co., Inc. $MRK Shares Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 108.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,761 shares of the company’s stock after buying an additional 8,725 shares during the quarter. Fox Run Management L.L.C.’s holdings in Merck & Co., Inc. were worth $1,327,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also modified their holdings of MRK. Peoples Financial Services CORP. boosted its holdings in Merck & Co., Inc. by 0.5% in the second quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company’s stock worth $1,803,000 after purchasing an additional 122 shares during the period. McLean Asset Management Corp lifted its position in shares of Merck & Co., Inc. by 3.7% in the 2nd quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock worth $292,000 after buying an additional 125 shares during the last quarter. Cora Capital Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 2.4% in the 2nd quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company’s stock valued at $423,000 after buying an additional 125 shares during the period. Saiph Capital LLC boosted its holdings in shares of Merck & Co., Inc. by 3.7% in the 1st quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock valued at $320,000 after buying an additional 128 shares during the period. Finally, Physician Wealth Advisors Inc. grew its position in shares of Merck & Co., Inc. by 2.9% during the 2nd quarter. Physician Wealth Advisors Inc. now owns 4,587 shares of the company’s stock valued at $363,000 after buying an additional 128 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Michael Williams sold 8,614 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $83.59, for a total transaction of $720,044.26. Following the sale, the executive vice president directly owned 24,578 shares in the company, valued at approximately $2,054,475.02. The trade was a 25.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Trading Up 0.7%

Shares of MRK stock opened at $86.34 on Friday. Merck & Co., Inc. has a 1 year low of $73.31 and a 1 year high of $105.07. The firm has a market capitalization of $215.66 billion, a PE ratio of 13.30, a price-to-earnings-growth ratio of 0.95 and a beta of 0.34. The stock has a fifty day moving average of $84.59 and a two-hundred day moving average of $82.06. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.17 and a current ratio of 1.42.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, October 30th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.36 by $0.22. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company had revenue of $17.28 billion for the quarter, compared to analyst estimates of $17 billion. During the same period last year, the company earned $1.57 earnings per share. The company’s quarterly revenue was up 3.7% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, research analysts expect that Merck & Co., Inc. will post 9.01 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a report on Saturday. Berenberg Bank cut Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price target for the stock from $100.00 to $90.00 in a research report on Wednesday, September 17th. Weiss Ratings restated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday, October 8th. Morgan Stanley upped their price objective on Merck & Co., Inc. from $98.00 to $100.00 and gave the stock an “equal weight” rating in a research note on Monday, November 3rd. Finally, Citigroup began coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They issued a “neutral” rating and a $95.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Hold” and a consensus price target of $104.47.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.